At any rate, similar analyses can be developed for non-FDG tracers, e.g. with SSTR ligands in neuroendocrine tumors and PSMA ligands in prostate cancer, Na18F in breast and prostate cancer patients (184–187). Here, FOLH1 is linked to Familial prostate cancer.